Oxycodone Market Trends, Regulations and Competitive Landscape Outlook by 2031 | FMI Study

 According to a newly updated analysis from Future Market Insights, Oxycodone Market will increase steadily between 2021 and 2031 at a CAGR of 4.8%. The market for oxycodone is expected to reach a value of over US$ 4.6 Billion in 2021, driven by a surge in demand for efficient pain treatment options.



Due to rising healthcare costs in the United States and Canada, growth estimates for North America are nevertheless optimistic. The price of oxycodone in North America is anticipated to reach US$ 1.85 Billion in 2021 as a result of this.

Request a Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-7638

Oxycodone belongs to a group of opioid analgesics that are generally used in pain management. It is used for both long and short term. Rising prevalence of orthopaedic diseases such as osteoporosis, fibromyalgia, rheumatoid arthritis and other types of chronic pain is boosting the demand for oxycodone in the global market.

According to the International Osteoporosis Foundation, osteoporosis is one of the most serious health concerns among women and around 30% of people in U.S and Europe are affected by it each year. Increasing medical ailment and post-operative pain is another factor influencing the demand for oxycodone market globally.

The market growth is expected to accelerate due to increasing research and development activities undertaken to innovate abuse-deterrent formulations. Advance drug formulation such as extended-release medication for pain relief is an example of improve formulation.

The market however could face certain restrains in growth as oxycodone has side effects such as bladder pain, abdominal cramps, vomiting, diarrhoea, and breathing problem. Moreover, overdose of oxycodone can lead to de-addiction. The market can also be impacted due to certain severe adverse psychological problems such as depression.

For more information: https://www.futuremarketinsights.com/reports/oxycodone-market

Key Takeaways from FMI’s Oxycodone Market Study

  • Increasing penetration of pain management drugs, coupled with favourable reimbursement policies will drive sales in the U.S.
  • Within the Middle East and Africa, the demand in GCC countries will rise backed by investment towards expansion of the healthcare sector
  • The U.K., Italy, and France are likely to account for sizeable share in the Europe market for oxycodone
  • Long-acting oxycodone sales will rise steadily owing to surging application in pain management
  • Hospital pharmacies will continue exhibiting high demand for oxycodone, driven by higher footfall of patients

Who is Winning?

  • FDA in 2017 approved RoxyBond, a novel formulation of immediate-release oxycodone. This is the first approved immediate release opioid analgesic formulation with labelling that describes its abuse-deterrent properties.
  • In September 2019, Daiichi Sankyo Company in Japan, launched its generic formulated oxycodone hydrochloride hydrate extended release tablets for cancer pain treatment.

Roxicodone is a prescription medication that is used to manage moderate to severe pain. It belongs to a class of drugs called opioid analgesics and works by binding to opioid receptors in the brain and spinal cord, which can result in pain relief.

Oxycodone can be habit-forming and is classified as a Schedule II controlled substance by the United States Drug Enforcement Administration (DEA), which means it has a high potential for abuse and dependence.

Key Companies Profiled:

  • Teva Pharmaceutical Industries Ltd.
  • Purdue Pharma L.P
  • Daiichi Sankyo
  • Acorda Therapeutics
  • Teikoku Pharma USA, Inc.
  • Mylan N.V
  • Endo Pharmaceuticals Inc.
  • Janssen Pharmaceuticals, Inc.

Key Segments Covered in Oxycodone Market Study

By Oxycodone Type:

  • Long-acting oxycodone
  • Short-acting oxycodone

By Application:

  • Pain Management
  • De-addiction

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more